Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ENLV |
---|---|---|
09:32 ET | 139 | 1.4 |
09:34 ET | 2000 | 1.42 |
09:45 ET | 1907 | 1.4 |
10:01 ET | 1200 | 1.4 |
10:46 ET | 335 | 1.415 |
11:29 ET | 100 | 1.4038 |
11:33 ET | 1550 | 1.4 |
11:49 ET | 987 | 1.4009 |
12:05 ET | 1400 | 1.39 |
12:07 ET | 294 | 1.39 |
12:34 ET | 200 | 1.395 |
12:39 ET | 730 | 1.4 |
02:13 ET | 140 | 1.415 |
03:20 ET | 1500 | 1.4254 |
03:38 ET | 112 | 1.41 |
03:48 ET | 100 | 1.41 |
03:59 ET | 462 | 1.4 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Enlivex Therapeutics Ltd | 26.7M | -0.9x | --- |
UNITY Biotechnology Inc | 25.7M | -0.6x | --- |
NKGen Biotech Inc | 25.6M | -0.3x | --- |
Biora Therapeutics Inc | 25.7M | -0.1x | --- |
Iterum Therapeutics PLC | 24.7M | -0.6x | --- |
Eom Pharmaceutical Holdings Inc | 23.8M | -4.8x | --- |
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.